TBCE and metabolic dysfunction-associated steatohepatitis: FXR activation exerts pleiotropic effects in intestinal enterocytes, hepatocytes, KCs, or HSCs [39,40], which results in improvement in steatosis, inflammation, and fibrosis in preclinical NASH animal models [39,40].